The global intravenous immunoglobulin market size was valued at USD 6,637.4 million in 2014. The increasing prevalence of target disorders such as autoimmune, hematological, and neurological diseases and rising use of off-label indications with high unmet clinical needs in developing countries are expected to serve as high growth rendering drivers.
The increasing demand for IVIG therapies for the treatment of primary immunodeficiency diseases is the most prominent factor attributing to industry growth as it is the most effective and the only available treatment option. Immunodeficiency diseases are of two types, primary and acquired immunodeficiency diseases including AIDS and X-linked Hypogammaglobulinemia. Growing incidences of these diseases are expected to boost the demand for immunoglobulin therapies in the coming years.
Furthermore, the growing geriatric population prone to antibody deficiency disorders due to a weak immune system is further anticipated to propel the demand for IVIG treatment in the future.
North America intravenous immunoglobulin market, by application 2012 - 2022 (USD Million)
Application in hypogammaglobulinemia diseases accounted for the largest revenue share in 2014 at over 21.0% as it was the most common chronic immune defect in patients with LPDs and treated with IVIG therapy. According to estimates published by the CDC in 2012, the global incidence rate of hypogammaglobulinemia was approximately 2 per 100,000 persons per annum and this is expected to increase in the coming years which is expected to widen consumer base of this market in near future.
IVIG are administered as a first line treatment product for the Kawasaki disease management and this disease market segment is anticipated to register a lucrative growth over the forecast period. The increasing incidence rate of antibody deficiency diseases and patient awareness levels are anticipated to further fuel the demand of IVIG products over the forecast period.
Route of Administration Insights
Intravenous immunoglobulin accounted for the largest share, at over 80.0% of total immunoglobulin market in 2014, as it is the most commonly used first line treatment for patients with primary immunodeficiency disorders. Subcutaneous immunoglobulin market is expected to exhibit the fastest growth rate during the forecast period due to its associated benefits,such as easy and shorter administration duration, reduced need for hospital resources, and extensive product pipeline awaiting approval, over the forecast period.
The North American IVIG market was the largest, with a share of above 47.0% in 2014. The presence of favorable government initiatives pertinent to product development and sophisticated healthcare infrastructure, high patient awareness levels, and higher healthcare expenditure in this region are some prominent factors contributing towards regional market growth.
The Asia Pacific intravenous immunoglobulin market is expected to exhibit a lucrative growth from 2014 to 2022 due to the increasing prevalence of immunodeficiency in pediatric as well as in geriatric population and improving healthcare infrastructure. European countries such as UK and Germany are also expected to register an impressive CAGR over the forecast period of above 7.0% due to rising population base with neurological disorders.
Competitive Market Share Insights
The companies that dominate the global intravenous immunoglobulin industry share include Baxter international, Inc., Grifols S.A., Kedrion Pharma, Octapharma AG, LFB Group, Biotest AG, China Biologics Products Ltd., and CSL Limited. The industry is competitive in nature marked by high industry rivalry levels. The players are striving hard to gain a competitive advantage by capitalizing on available untapped opportunities.
The companies are adopting varied competitive strategies to increase their market share such as new product development, mergers & acquisitions, and strategic alliances. For example, in March 2015, Baxter acquired company SuppreMol including the company’s pipeline portfolio for allergic and autoimmune diseases. This acquisition resulted in Baxter’s differentiated immunology product portfolio.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.